22nd Century Group (XXII) Falls Following FDA Feedback on Very Low Nicotine MRTPA Filings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Chardan Capital Weighs in on 22nd Century Group (XXII) as FDA Responds to MRTP Application
January 5, 2017 12:56 PM ESTChardan Capital Markets analyst James McIlree weighed in on 22nd Century Group (NYSE: XXII) after the company company announced that the FDA has provided the Company with helpful and positive feedback on the Companys combined Modified Risk Tobacco Product Applications (MRTPAs) and Premarket Tobacco Product Applications (PMTAs) for 22nd Centurys BRAND A Very Low Nicotine tobacco cigarettes.
"We did not... More
